Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
106M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
47.1M
-
Shares change
-
+4.06M
-
Total reported value, excl. options
-
$1.12B
-
Value change
-
+$92.6M
-
Put/Call ratio
-
0.93
-
Number of buys
-
86
-
Number of sells
-
-48
-
Price
-
$23.79
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q2 2023
167 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q2 2023.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.1M shares
of 106M outstanding shares and own 44.52% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.12M shares), VR Adviser, LLC (3.08M shares), STATE STREET CORP (2.92M shares), VANGUARD GROUP INC (2.6M shares), Paradigm Biocapital Advisors LP (2.42M shares), COMMODORE CAPITAL LP (2.2M shares), RA CAPITAL MANAGEMENT, L.P. (2.01M shares), PERCEPTIVE ADVISORS LLC (1.78M shares), Vivo Capital, LLC (1.68M shares), and Polar Capital Holdings Plc (1.6M shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.